Lannacheng Biotech Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Investors
  • 12

Lannacheng Biotech General Information

Description

Developer of oncological nuclear medicine platform designed for cancer treatment. The company focuses on building a global platform for innovative nuclear medicine for the diagnosis and treatment of various types of cancer, providing the healthcare and oncology sectors with comprehensive, innovative solutions for cancer care.

Contact Information

Website
www.dc-lnc.com
Formerly Known As
Shanghai Lannacheng Biotechnology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 101, Building 52, Number 500, Binhai East Road
  • Muping District
  • Yantai, Shandong 264100
  • China
+86 0535
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 101, Building 52, Number 500, Binhai East Road
  • Muping District
  • Yantai, Shandong 264100
  • China
+86 0535

Lannacheng Biotech Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lannacheng Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. IPO 13-Oct-2026 Cancelled Generating Revenue
6. Later Stage VC (Series C1) 18-Jul-2025 Completed Generating Revenue
5. Later Stage VC (Series C) 14-Feb-2025 Completed Clinical Trials - General
4. Early Stage VC (Series B1) 24-Apr-2024 Completed Pre-Clinical Trials
3. Early Stage VC 27-Nov-2023 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 23-Jun-2023 $28.1M $28.1M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Jun-2022 Completed Startup
To view Lannacheng Biotech’s complete valuation and funding history, request access »

Lannacheng Biotech Patents

Lannacheng Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022170732-A1 Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof Inactive 10-Feb-2021

Lannacheng Biotech Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
China Cinda Asset Management Corporation Minority
Inner Mongolia New Energy Investment Funds Management Government Minority
Shanghai Rui Investment Fund Management Asset Manager Minority
Qianhai FoF Fund of Funds Minority
Shenzhen Capital Group Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Lannacheng Biotech FAQs

  • When was Lannacheng Biotech founded?

    Lannacheng Biotech was founded in 2021.

  • Where is Lannacheng Biotech headquartered?

    Lannacheng Biotech is headquartered in Yantai, China.

  • What industry is Lannacheng Biotech in?

    Lannacheng Biotech’s primary industry is Drug Discovery.

  • Is Lannacheng Biotech a private or public company?

    Lannacheng Biotech is a Private company.

  • What is Lannacheng Biotech’s current revenue?

    The current revenue for Lannacheng Biotech is .

  • How much funding has Lannacheng Biotech raised over time?

    Lannacheng Biotech has raised $132M.

  • Who are Lannacheng Biotech’s investors?

    China Cinda Asset Management, Inner Mongolia New Energy Investment Funds Management, Shanghai Rui Investment Fund Management, Qianhai FoF, and Shenzhen Capital Group are 5 of 12 investors who have invested in Lannacheng Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process